• Appoints leading US gynaecologic oncologist Dr Nicholas Lambrou as first Key Opinion Leader
• Dr Lambrou to support clinical advocacy, publication development, and presentation of CLEO's technology
• KOL engagement represents a key US market entry activity as part of CLEO's commercialisation strategy

Cleo Diagnostics Limited (ASX:COV) has announced the appointment of leading US gynaecologic oncologist, Dr Nicholas Lambrou, as the company's first Key Opinion Leader (KOL). Dr Lambrou is a highly respected US-based surgeon, clinical advisor, and researcher with extensive expertise in oncology, gynaecologic surgery, and women's health. Under the agreement, Dr Lambrou will support Cleo in clinical and medical review of its research, data, and publications, provide advisory input on data interpretation and presentation materials, and present Cleo's research findings at scientific meetings and congresses in the US. Establishing a network of respected US KOLs is a core pillar of Cleo's early-market engagement strategy, supporting clinical validation, awareness-building, and early adoption among specialist clinicians. Dr Lambrou's presence and influence within the US healthcare ecosystem, particularly among gynaecologic oncologists, surgeons, and women's health centres, will play a central role in Cleo's US market entry activities. His clinical expertise and visibility will help the company accelerate introduction of its Pre-Surgical Ovarian Cancer Test technology into the US and provide independent, practice-based insights to support market education and uptake.

Cleo expects to expand its KOL and advisory network as it moves through key development, regulatory, and commercialisation milestones for its Pre-Surgical Ovarian Cancer Test.